Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1331-1336

  Sudo, Roberto T ^a   Nelson, Thomas E ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RYANODINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOG; DRUG EFFECT; KINETICS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RYANODINE;

EID: 0030961203     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. BRITT, B. A. AND KALOW, W.: Malignant hyperthermia: aetiology unknown. Can. Anaesth. Soc. J. 17: 316-330, 1970.
2. 2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs. Biochem. Biophys. Acta 1064: 175-183, 1991.
3. 2+ release regulation in junctional sarcoplasmic reticulum. Arch. Biochem. Biophys. 290: 239-247, 1991.
4. CHU, A., DIAZ-MUÑOZ, M., HAWKES, M. J., BRUSH, K. AND HAMILTON, S. L.: Ryanodine as a probe for the functional state of the skeletal muscle sarcoplasmic reticulum calcium release channel. Mol Pharmacol. 37: 735-741, 1990.
5. CORONADO, R., MORRISSETTE, J., SUKHAREVA, M. AND VAUGHAN, D. M.: Structure and function of ryanodine receptors. Am. J. Physiol. 286: C1485-C1504, 1994.
6. DEUFEL, T., SUNDBRAK, R., FEIST, Y., RUBSAM, B., DU CHESNE, I., SCHAFER, K. L., ROEWER, N., GRIMM, T., LEHMANN-HORN, F., HARTUNG, E. J. AND MÜLLER, C. R.: Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am. J. Hum. Genet. 56: 1334-1342, 1995.
7. THE EUROPEAN MALIGNANT HYPERPYREXIA GROUP. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br. J. Anaesth. 56:1267-1269, 1984.
8. FUJII, J., OTSU, K., ZORZATO, F., DE LEON, S., KHANNA V. K., WEILER, J. E., O'BRIEN, P. J. AND MACLENNAN, D. H.: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448-451, 1991.
9. GILLARD, E. F., OTSU, K., FUJII, J., KHANNA, V. K., DE LEON, S., DERDEMEZI, J., BRITT, B. A., DUFF, C. L., WORTON, R. G. AND MACLENNAN, D. H.: A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11: 751-755, 1991,
10. HARTUNG, E., KOOB, M., ANETSEDER, M., SCHOEMIG, P., KRAUSPE, R., HOGREFE, G. AND ENGELHARDT, W.: Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine-and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol. Scand. 40: 437-444, 1996.
11. 2+-release channel in malignant hyperthermia. J. Biol. Chem. 267: 6702-6709, 1992.
12. HOPKINS, P. M., ELLIS, F. R. AND HALSALL, P. J.: Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br. J. Anaesth. 66: 611-613, 1991.
13. 2+ release channel complex of skeletal muscle sarcoplasmic reticulum. Evidence for a cooperativity coupled, negatively charged homotetramer. J. Biol. Chem. 264: 16776-16785, 1989.
14. LARACH, M. G.: Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth. Analg. 69: 511-515, 1989.
15. LARACH, M. G., LOCALIO, A. R., ALLEN, G. C., DENBOROUGH, M. A., ELLIS, F. R., GRONERT, G. A., KAPLAN, R. F., MULDOON, S. M., NELSON, T. E., ØRDING, H., ROSENBERG, H., WAUD, B. E. AND WEDEL, D. J.: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80: 771-779, 1994.
16. LENZEN, C., ROEWER, N., WAPPLER, F., SCHOLZ, J., KAHL, J., BLANK, M., RUMBERCER, E. AND SCHULTE AM ESCH, J.: Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br. J. Anaesth. 71: 242-246, 1993.
17. 2+] during a malignant hyperthermia episode in swine. Muscle Nerve 11: 82-88, 1988.
18. MCCARTHY, T. V., HEALY, J. M., HEFFRON, J. J., LEHANE, M., DEUFEL, T., LEHMANN-HORN, F., FARRALL, M. AND JOHNSON, K.: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343: 562-564, 1990.
19. MACLENNAN, D. H., DUFF, C., ZORZATO, F., FUJII, J., PHILLIPS, M., KORNELUK, R. G., FRODIS, W., BRITT, B. A. AND WORTON, R. G.: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343: 559-561, 1990.
20. MACLENNAN, D. H.: Discordance between phenotype and genotype in malignant hyperthermia. Curr. Opin. Neurol. 8: 397-401, 1995.
21. MICKELSON, J. R., GALLANT, E. M., LITTERER, L. A., JOHNSON, K. M., REMPEL, W. E. AND LOUIS, C. F.: Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 263: 9310-9315, 1988.
22. NELSON, T. E.: Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J. Clin. Invest. 72: 862-870, 1983.
23. NELSON, T. E.: Malignant hyperthermia in dogs. J. Am. Vet. Med. Assoc. 198: 989-994, 1991.
24. 2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J. Biol. Chem. 269: 9413-9415, 1994.
25. 2+ release channel of sarcoplasmic reticulum from skeletal and cardiac muscle: evidence for a sequential mechanism in ryanodine action. Mol. Pharmacol. 39: 679-689, 1991.
26. 2+ release channel. Am. J. Physiol. 253: C364-C368, 1987.
27. 2+ release channels demonstrated with caffeine-induced tension transients in skinned striated and vascular smooth muscle. Adv. Exp. Med. Biol. 311: 439-443, 1992a.
28. 2+ on ryanodine depression of the tension transient in skinned myocardial fibers of the rabbit. Pflügers Arch. 421: 1-6, 1992b.
29. ANONYMOUS: A protocol for the investigation of malignant hyperpirexia (MH) susceptibility. The European Malignant Hyperpirexia Group. Br. J. Anaesth. 56: 1267-1269, 1984.
30. WAPPLER, F., ROEWER, N., KÖCHLING, A., SCHOLZ, J., STEINFATH, M. AND SCHULTE AM ESCH, J.: In vitro Diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth. Analg. 82: 1230-1236, 1996.
31. ZIMANYI, I., BUCK, E., ABRAMSON, J. J., MACK, M. M. AND PESSAH, I. N.: Ryanodine induces persistant inactivation of the Ca 2+ release channel from skeletal muscle sarcoplasmic reticulum. Mol. Pharmacol. 42: 1049-1057, 1992.